

The feasibility of targeted test-trace-isolate for the control of B.1.1.7

William J. Bradshaw¹, Jonathan H. Huggins², Alun L. Lloyd³, and Kevin M. Esvelt^{4,*}

¹Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 296, 50937 Cologne, Germany

²Department of Mathematics & Statistics, Boston University, Boston, MA 02215, USA

³Biomathematics Graduate Program and Department of Mathematics, North Carolina State University, Raleigh, NC 27695, USA

⁴Media Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

* For correspondence: esvelt@mit.edu

Abstract

The SARS-CoV-2 variant B.1.1.7 reportedly exhibits substantially higher transmission than the ancestral strain and may generate a major surge of cases before vaccines become widely available. As B.1.1.7 can be sensitively detected using the Thermo Fisher TaqPath S-gene RT-PCR test, contact tracing and isolation programs appear well-suited to slowing the spread of the new variant, which is still rare in most of the dozens of countries in which it has been identified. However, key determinants of outcomes such as data-sharing, trace success, and isolation compliance vary widely between regions, which may discourage public health agencies from explicitly redirecting existing contact tracers to contain B.1.1.7. Here we apply a branching-process model to estimate the effectiveness of implementing a B.1.1.7-focused testing, contact tracing, and isolation strategy with realistic levels of performance. Our model indicates that bidirectional contact tracing can substantially slow the spread of B.1.1.7 even in regions where a large fraction of the population refuses to cooperate with contact tracers or to abide by quarantine and isolation requests.

The frequency of the B.1.1.7 variant of SARS-CoV-2 has grown rapidly from its initial detection in October 2020 to become the dominant strain in southeastern England by 2021. Studies have estimated the new strain is between 40% and 80% more contagious^{1,2}. The rapid exponential growth of B.1.1.7, which is now found in dozens of countries, risks another and potentially higher wave of COVID-19 cases prior to widespread vaccination.

Due to the B.1.1.7 variant's characteristic $\Delta 69-70$ mutation in the spike protein, cases of the new variant can be sensitively detected and distinguished from the ancestral SARS-CoV-2 via a Thermo Fisher TaqPath RT-PCR diagnostic test for COVID-19³. Twenty million such kits are manufactured weekly⁴. As such, existing COVID-19 testing infrastructure can be used to track the transmission of the new variant. Samples testing positive by other kits can be re-screened⁵ without an emergency use authorization.

Test-trace-isolate (TTI) strategies have been widely used to mitigate the spread of SARS-CoV-2⁶. Models by the present authors⁷ and others⁸ have found that incorporating backwards tracing to identify infector individuals could dramatically increase the efficacy of tracing programs. However, testing delays, mistrust, and low compliance in some communities have undermined the confidence of health authorities in the benefits of TTI^{9,10}. Moreover, efficacy sharply decreases when caseloads are high¹¹, as is

true for SARS-CoV-2 – but not yet B.1.1.7^{12,13} – in many regions.

Given the current low prevalence of B.1.1.7 in most jurisdictions and the ability to identify cases of the new variant using existing testing infrastructure, we hypothesised that TTI programs dedicated to controlling B.1.1.7 could substantially reduce the harm inflicted by the new variant prior to widespread vaccination of populations later in 2021. Such programs could be enhanced through incorporation of bidirectional tracing.

However, the effectiveness of TTI strategies varies widely from region to region due to programmatic and population-level differences in variables such as the proportion of cases who share their contact history with contact tracers; the proportion who comply with quarantine and isolation requests; and the overall rate of tracing success. Given this variation, it is unclear whether tracing programs exhibiting realistic levels of performance could feasibly dampen the spread of B.1.1.7.

To evaluate the potential benefits of applying targeted test-trace-isolate to control B.1.1.7, we applied a previously published branching-process model of COVID-19 contact tracing⁷ to estimate the change in the effective reproduction number achievable across a wide range of parameters.

Methods

In our model, each case generates a number of new cases drawn from a negative binomial distribution, according to some pre-specified incubation- and generation-time distributions (Table 1). Cases could be identified and isolated based on symptoms alone or through contact tracing. Cases were assumed to either comply with quarantine and isolation requests, or ignore them completely, according to some fixed probability of compliance; cases that comply with quarantine & isolation were assumed to generate no further cases.

Successful tracing depended on the identified case sharing their contact history with tracers, and on the contact in question taking place within the time window (measured in days pre-symptom onset for symptomatic cases, and days pre-identification for asymptomatic cases). Environmental transmission was assumed to be untraceable. Symptomatic cases required a positive test before initiating contact tracing, as in the EU¹⁴ and most US jurisdictions.

Each outbreak was initialized with 20 index cases to minimize stochastic extinction and designated as “controlled” if it reached extinction (zero new cases) before reaching 10,000 cumulative cases. Effective reproduction numbers (R_{eff}) were computed as the mean number of child cases produced per case.

Results

To investigate the potential for TTI to mitigate the spread of B.1.1.7, we investigated the effective reproduction number achieved across a range of data-sharing and trace-success rates (Figure 1). To account for uncertainty in the transmissibility of B.1.1.7, we explored outcomes for reproduction numbers between 1.2 and 2.0; these values assume that non-tracing interventions are already in place.

In the absence of contact tracing, identification and isolation of symptomatic cases alone reduced R_{eff} by 0.2 to 0.3 even when quarantine and isolation compliance was low (Figure 1, top rows). When identification and isolation left R_{eff} substantially greater than 1 (when base $R \geq 1.4$), moderate levels of tracing could have substantial effects.

When contacts were traced up to 2 days prior to symptom onset, roughly 60-70% data sharing and trace success was required to achieve an R_{eff} reduction of at least 0.1, relative to isolation alone. If the window was extended to 6 days pre-onset to enable more effective bidirectional tracing, roughly 45-55% data sharing and trace success was sufficient. Higher levels of data sharing and trace success could achieve substantially larger reductions: in many scenarios, 85% data sharing and trace success reduced R_{eff} by >0.2 in the 2-day case and >0.35 in the 6-day case.

Due to the exponential growth of uncontrolled epidemics, small reductions in R_{eff} can have a large impact on the total number of downstream cases arising from a given index case over a given timespan. For example, under a simple geometric series approach, reducing R_{eff} by 0.1 from a starting value between 1.2 and 2.0 reduces the total number of child cases after 10 generations by 37-43%; an R_{eff} reduction of 0.2 results in a reduction in child cases of 61-66%. Given an average generation time of 6 days, 10 generations equates to roughly 2 months – enough time, given sufficient delay in the spread of the new variant, to vaccinate a substantial fraction of the population.

Discussion

Our results suggest that regions with even moderately functional contact tracing programs focused on B.1.1.7 could substantially slow the spread of the variant. Given a 2-day window for bidirectionally tracing contacts pre-symptom onset, our model predicts that a program with 70% trace success, 70% data sharing, and 70% compliance with isolation could achieve an R_{eff} reduction of at least 0.1 relative to the no-tracing case. Given a 6-day window for efficient bidirectional tracing, regions with just 50% data-sharing, trace success, and isolation compliance could achieve a reduction of 0.1.

Under simple assumptions, such a reduction would reduce the number of child cases produced in two months by roughly 40%, buying time for vaccination to immunise many more people. More effective tracing programs can achieve larger reductions. Higher rates of cooperation might be achieved through home visits by contact tracers¹⁵; exoneration for anything discovered in the course of B.1.1.7 contact tracing¹⁰; and financial and other support of people in quarantine and isolation¹⁶. In principle, concentrating vaccination in communities with clusters of uncontrollable B.1.1.7 transmission could further impair viral spread and increase the sustainability of testing, tracing, and isolation for the control of COVID-19.

These results assume a high availability of suitable tests for B.1.1.7, and a rapid and consistent testing turnaround. They also take no account of any medical, demographic, geospatial or behavioural variation between cases which could influence the spread of the new variant.

Our results suggest that TTI programs could help slow the spread of B.1.1.7 in regions where it is currently rare, providing vital time for vaccination to end the COVID-19 pandemic. As TTI efficacy is limited at high caseloads¹¹, these findings indicate that tracing programs should immediately prioritise controlling B.1.1.7 over less transmissible – but currently more widespread – strains.




Figure 1. Evaluating the efficacy of bidirectional contact tracing for controlling B.1.1.7. Neighbour-averaged contour plots, showing R_{eff} achieved by bidirectional manual contact tracing with a tracing window of (a) 2 or (b) 6 days pre-symptom onset, under different combinations of trace success probability (x-axis), rate of data sharing with manual contact tracers (y-axis), rate of compliance with isolation and quarantine (row) and base reproduction number (columns). Other disease parameters are specified in Table 1. Isolation of symptomatic cases is sufficient to reduce R even when no traces succeed and/or no cases share their data with contact tracers. “Trace success probability” refers to trace attempts that are not otherwise blocked by environmental transmission or refusal to share data.

References

1. Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv* (2021) doi:10.1101/2020.12.30.20249034.
2. Public Health England. Investigation of novel SARS-COV-2 variant – Variant of Concern 202012/01. (2020).
3. Bal, A. *et al.* Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70, Lyon, France, August to December 2020. *medRxiv* (2020) doi:10.1101/2020.11.10.20228528.
4. Thermo Fisher representatives. (2021).
5. Lopez-Rincon, A. *et al.* Design of Specific Primer Set for Detection of B.1.1.7 SARS-CoV-2 Variant using Deep Learning. *Cold Spring Harbor Laboratory* 2020.12.29.424715 (2020) doi:10.1101/2020.12.29.424715.
6. Koetter, P. *et al.* Implementation and Process of a COVID-19 Contact Tracing Initiative: Leveraging Health Professional Students to Extend the Workforce During a Pandemic. *Am. J. Infect. Control* **48**, 1451–1456 (2020).
7. Bradshaw, W. J., Alley, E. C., Huggins, J. H., Lloyd, A. L. & Esvelt, K. M. Bidirectional contact tracing is required for reliable COVID-19 control. *medRxiv* (2020) doi:10.1101/2020.05.06.20093369.
8. Endo, A. *et al.* Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak. *medRxiv* (2020) doi:10.1101/2020.08.01.20166595.
9. Lewis, D. Why many countries failed at COVID contact-tracing - but some got it right. *Nature* **588**, 384–387 (2020).
10. Megnin-Viggars, O., Carter, P., Melendez-Torres, G. J., Weston, D. & Rubin, G. J. Facilitators and barriers to engagement with contact tracing during infectious disease outbreaks: A rapid review of the evidence. *PLoS One* **15**, e0241473 (2020).
11. Contreras, S. *et al.* The challenges of containing SARS-CoV-2 via test-trace-and-isolate. *arXiv [q-bio.PE]* (2020).
12. Helix, Illumina launch surveillance program as the B.1.1.7 variant of SARS-CoV-2, first identified in the UK, spreads further into the US. <https://blog.helix.com/b117-variant-updated-data/> (2021).
13. Statens Serum Institut. Ny status på forekomsten af cluster B.1.1.7 i Danmark. <https://www.ssi.dk/aktuelt/nyheder/2021/ny-status-pa-forekomst-af-cluster-b117-i-danmark>.
14. European Centre for Disease Prevention. *Contact tracing: Public health management of persons, including healthcare workers, having had contact with COVID-19 cases in the European Union - second update*. <https://www.ecdc.europa.eu/en/covid-19-contact-tracing-public-health-management> (2020).
15. Bebinger, M. Massachusetts contact tracers can help with ordering groceries or rent: here's how. <https://www.masslive.com/coronavirus/2020/08/massachusetts-contact-tracers-can-help-with-ordering-groceries-or-rent-heres-how.html> (2020).
16. Bodas, M. & Peleg, K. Self-Isolation Compliance In The COVID-19 Era Influenced By Compensation: Findings From A Recent Survey In Israel. *Health Aff.* **39**, 936–941 (2020).
17. Lavezzo, E. *et al.* Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv* (2020) doi:10.1101/2020.04.17.20053157.
18. Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2006100.
19. Ma, S. *et al.* Epidemiological parameters of coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases from seven countries. *medRxiv* (2020) doi:10.1101/2020.03.21.20040329.
20. Rivett, L. *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife* **9**, e58728 (2020).
21. Meyerowitz, E. A., Richterman, A., Bogoch, I. I., Low, N. & Cevik, M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. *Lancet Infect. Dis.* (2020) doi:10.1016/S1473-3099(20)30837-9.
22. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N. Engl. J. Med.* **382**, 1177–1179 (2020).
23. Hu, Z. *et al.* Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci. China Life Sci.* **63**, 706–711 (2020).
24. Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* **368**, 489–493 (2020).
25. Chau, N. V. V. *et al.* The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *medRxiv* (2020) doi:10.1101/2020.04.27.20082347.
26. Jing Cai *et al.* Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerging Infectious Disease journal* **26**, (2020).
27. Ferretti, L. *et al.* Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* (2020) doi:10.1126/science.abb6936.
28. Cheng, H.-Y. *et al.* Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern. Med.* (2020) doi:10.1001/jamainternmed.2020.2020.
29. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* (2020) doi:10.1038/s41591-020-0869-5.
30. Jing, Q.-L. *et al.* Household Secondary Attack Rate of COVID-19 and Associated Determinants. *medRxiv* (2020) doi:10.1101/2020.04.11.20056010.
31. Zhanwei Du *et al.* Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. *Emerging Infectious Disease journal* **26**, (2020).
32. Wei, W. E. *et al.* Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 411–415 (2020).
33. Ganyani, T. *et al.* Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. *Eurosurveillance* **25**, 2000257 (2020).
34. Golding, N. *et al.* Reconstructing the global dynamics of under-ascertained COVID-19 cases and infections. *medRxiv* (2020) doi:10.1101/2020.07.07.20148460.
35. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/ciaa344.
36. Whitman, J. D. *et al.* Test performance evaluation of SARS-CoV-2 serological assays. *medRxiv* (2020) doi:10.1101/2020.04.25.20074856.
37. Endo, A., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* **5**, 67 (2020).
38. Lauer, S. A. *et al.* The incubation period of 2019-nCoV from publicly reported confirmed cases: estimation and application. *medRxiv* (2020) doi:10.1101/2020.02.02.20020016.
39. Griffin, J. *et al.* Rapid review of available evidence on the serial interval and generation time of COVID-19. *BMJ Open* **10**, e040263 (2020).
40. Hellewell, J. *et al.* Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. *Lancet Glob Health* **8**, e488–e496 (2020).
41. McCann, L., Allan, W., Read, P. & McNulty, A. Contact tracing using provider referral: how difficult is it? *Sex. Health* **10**, 472–473 (2013).

Acknowledgments: We thank Aaron Bucher of the COVID-19 HPC Consortium and Amazon Web Services for granting us extra cloud compute credits.

Funding: This work was supported by gifts from the Reid Hoffman Foundation and the Open Philanthropy Project (to K.M.E.) and cluster time granted by the COVID-19 HPC consortium (MCB20071 to K.M.E.). A.L.L. is supported by the Drexel Endowment (NC State University) and by the award CDC U01CK000587-01M001 from the US Centers for Disease Control and Prevention. The funders had no role in the research, writing, or decision to publish.

Author Contributions: K.M.E. conceived the study. J.H.H. and A.L.L. identified a suitable model framework. W.J.B.

designed and programmed the adapted model, advised by the other authors. W.J.B. ran all simulations and generated figures. All authors jointly wrote and edited the manuscript.

Data Availability: The data supporting the findings of this study are in the main manuscript and the Supplementary Information, and are available at <https://github.com/willbradshaw/covid-bidirectional-tracing>.

Code Availability: Code for configuring and running the model is publicly available at <https://github.com/willbradshaw/covid-bidirectional-tracing>.

Competing Interests: The authors declare no competing interests.

Table 1: Parameters of the branching-process model.

Parameter	Value	Sources and Notes
% asymptomatic carriers	40%	^{17–21}
Relative infectiousness of asymptomatic carriers	45%	Informed by viral loads and tracing results described in ^{17,21–25}
% environmental transmission	5%	^{26,27}
Proportion of pre-symptomatic transmission	38%	Informed by ^{21,22,24,25,28–33}
Generation time skew parameter (α)	0.397	Corresponds to pre-symptomatic transmission rate specified above.
% of symptomatic cases identified without tracing	50%	³⁴
% of cases who comply with isolation	50%, 70%, 90%	Assumed
Test sensitivity	70%	^{35,36}
R_{base} (before test/trace/isolate)	1.0 to 2.0	Assumes a pre-B.1.1.7 R of $\sim 1.0^{1,2}$.
Overdispersion	0.11	³⁷
Number of initial cases	20	Assumed
Incubation period	6.0 \pm 2.1 days (lognormal distribution)	^{1,38,39}
Delay from onset to isolation	3.8 \pm 2.4 days (Weibull distribution)	⁴⁰
Delay for testing	1 \pm 0.3 days (gamma distribution)	Assumed
Delay for manual tracing	1.5 \pm 4.8 days (lognormal distribution); median 0.5 days	Previous reports suggest most contacts can be traced within one day, but some take longer ⁴¹